UCB.BR
BRUUCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Contexte du mouvement
Secteur- Le secteur (Health Care, XLV) a bougé de 1.59% : mouvement largement sectoriel.
Drivers prévisibles à venir
- Échéances d'options · 16/10/2026 (J+6)
- Rebalancement d'indices · 18/12/2026 (J+69)
Contexte quantitatif — information à titre indicatif, pas un conseil en investissement.
Dividendes & société
UCB.BR · EUR
Sources : yahoo. Informations à titre indicatif, pas un conseil.
Consensus analystes
Sources : yahoo. Consensus d'analystes sell-side — information à titre indicatif, pas un conseil en investissement.
Contenu réservé aux membres
Créez un compte gratuit pour accéder à l'intelligence de marché de UCB.BR : corrélations, insights IA et actualités.
Accès libre sur les actions et ETF les plus suivis
Actualités liées
Budget de l'Union européenne : l'Irlande propose une réduction des dépenses de 8 % - Les Echos
Budget de l'Union européenne : l'Irlande propose une réduction des dépenses de 8 % Les Echos
Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?
UCB (ENXTBR:UCB) just dedicated the future site of a large biologics manufacturing campus in Gwinnett County, Georgia, marking a roughly €2b U.S. expansion that investors may view as a long-horizon capacity build. For context, UCB’s €203.5 share price comes after a 90 day share price return that declined 14.17% and a one year total shareholder return that declined 20.16%. This is in contrast to the three and five year total shareholder returns of 158.52% and 115.49%, which point to stronger...
Actualités du 09 octobre 2026
Actualités du 09 octobre 2026 Boursorama
Patriot Mobile, opérateur de téléphonie mobile chrétien-conservateur, dépose une demande d'introduction en bou
Patriot Mobile, opérateur de téléphonie mobile chrétien-conservateur, dépose une demande d'introduction en bou Boursorama
Base Electron dépose en toute confidentialité une demande d'introduction en Bourse aux États-Unis
Base Electron dépose en toute confidentialité une demande d'introduction en Bourse aux États-Unis Boursorama
BOURSE DU CANADA-Le TSX enregistre sa plus forte hausse en cinq semaines alors que les anticipations de hausse
BOURSE DU CANADA-Le TSX enregistre sa plus forte hausse en cinq semaines alors que les anticipations de hausse Boursorama
Wall Street termine la semaine en hausse - Investir Les Echos
Wall Street termine la semaine en hausse Investir Les Echos
vVardis prépare son entrée à Wall Street après avoir triplé ses revenus
vVardis prépare son entrée à Wall Street après avoir triplé ses revenus Boursorama
UCB (UCBJY) Upgraded to Buy: Here's Why
UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observe
Is It Too Late To Consider UCB (ENXTBR:UCB) After A 195% Three Year Surge?
Investors may be wondering if UCB's share price still reflects good value after a strong run, or if most of the opportunity is already priced in. UCB's share price closed at €246.30, with a 1 year return of 68.3% and a 3 year return of 195.3%. The 7 day and 30 day returns of a 4.8% decline and a 0.4% decline suggest some recent cooling after a longer period of strength. Recent headlines around UCB have focused on its position in the pharmaceuticals and biotech space, as investors reassess...
A Look At UCB (ENXTBR:UCB) Valuation After Neurology Conference Data And Real World Results
Conference data puts UCB’s neurology pipeline in focus UCB (ENXTBR:UCB) is in the spotlight after presenting 21 neurology abstracts at the American Academy of Neurology 2026 meeting, including new real world data on developmental and epileptic encephalopathies and generalized myasthenia gravis. See our latest analysis for UCB. Despite a 1-day share price return of 1.32% to €246.3 after the neurology data updates, UCB’s recent 7-day and 90-day share price returns of 4.79% and 4.31% declines...
UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know
UCB (UCBJY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
UCB S.A. Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Technology Initiatives, ICT, Partnerships, Investments & Acquisitions, Network Map
UCB S.A. has key market opportunities in developing biopharmaceuticals addressing autoimmune and neurological diseases. Their focus on digital transformation, innovation, and tech partnerships aims to advance product launches and strategic initiatives in these therapeutic areas.Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: UCB - 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into the company's tech activ
Les données sont fournies à titre informatif. PunkMarket n'est pas un conseiller financier.